北京时间2024年11月4日,生物制药公司Travere Therapeutics, Inc.(TVTX.us)股价盘中一度大涨5.07%,报18.46美元/股。市场关注该公司股价短期剧烈波动的原因。
从公司基本面来看,Travere Therapeutics是一家专注于开发罕见肾脏、肝脏和代谢疾病疗法的生物制药公司。其管线产品sparsentan正处于针对肾小球硬化症和IgA肾病的后期临床阶段,预计将为这些罕见肾脏疾病患者带来新的治疗方案。
最新财报数据显示,该公司去年实现营收6290万美元,亏损5475万美元,每股亏损0.70美元,但从机构评级情况来看,高达88%的机构给予该股"买入"评级,预计公司业务长期前景向好。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.